Hepion Pharmaceuticals (HEPA) Insider Trading & Ownership $0.06 0.00 (-8.00%) As of 01:01 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Hepion Pharmaceuticals (NASDAQ:HEPA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.70%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$49,790.00Number OfInsiders Selling(Last 3 Years)0 Get HEPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Hepion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HEPA Insider Buying and Selling by Quarter Hepion Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/27/2023Peter WijngaardDirectorBuy50$152.50$7,625.00 11/24/2023Peter WijngaardDirectorBuy50$154.50$7,725.00 9/19/2023Peter WijngaardDirectorBuy20$282.00$5,640.00 9/18/2023Robert T FosterCEOBuy32$280.00$8,960.00 9/15/2023Peter WijngaardDirectorBuy40$280.00$11,200.00 9/15/2023Robert T FosterCEOBuy32$270.00$8,640.00 (Data available from 1/1/2013 forward) HEPA Insider Trading Activity - Frequently Asked Questions Who is on Hepion Pharmaceuticals's Insider Roster? The list of insiders at Hepion Pharmaceuticals includes Peter Wijngaard, and Robert T Foster. Learn more on insiders at HEPA. What percentage of Hepion Pharmaceuticals stock is owned by insiders? 4.70% of Hepion Pharmaceuticals stock is owned by insiders. Learn more on HEPA's insider holdings. Which Hepion Pharmaceuticals insiders have been buying company stock? The following insiders have purchased HEPA shares in the last 24 months: Peter Wijngaard ($32,190.00), and Robert T Foster ($17,600.00). How much insider buying is happening at Hepion Pharmaceuticals? Insiders have purchased a total of 224 HEPA shares in the last 24 months for a total of $49,790.00 bought. Hepion Pharmaceuticals Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Compensation: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical Director More Insider Trading Tools from MarketBeat Related Companies Sonnet BioTherapeutics Insider Transactions Galecto Insider Transactions Titan Pharmaceuticals Insider Transactions Sunshine Biopharma Insider Transactions Mustang Bio Insider Transactions Tharimmune Insider Transactions CNS Pharmaceuticals Insider Transactions Kazia Therapeutics Insider Transactions Lixte Biotechnology Insider Transactions Organovo Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Dividend Investors Looking for an Edge? 3 Stocks Insiders BoughtMeta's Institutional & Insider Data Fuels Bulls Despite DisparityTurbulence for Joby Shares: What's Behind the Recent Dip?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals This page (NASDAQ:HEPA) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.